Edit topics
Your ASH 2025
The biggest change in each topic you follow. Tap a card to read the brief.
{{p}}
How to read this
From ASH 2025
What was presented: results, numbers, safety.
Causaly insight
Causaly connects the abstracts with trials and papers: what changed, how results compare, what's open.
Open in Causaly
takes any insight further in Causaly Research, with every source. Free trial.
Acute myeloid leukemia
Causaly insight
Menin inhibitors move into first-line treatment
Overall response, each dot one study
{{s.label}}
{{s.span}}
Response rates were highest in newly diagnosed patients, and the 2025 approvals came for relapsed disease.
Read the brief →
Multiple myeloma
Causaly insight
A bispecific beats standard care in early relapse
Progression-free at 3 years, MajesTEC-3
Tec + dara
83%
Standard
30%
The first randomized survival win for a T-cell engager, with more serious infections as the trade-off.
Read the brief →
{{t.name}}
Brief not built yet
Ready to explore now:
Menin inhibitors in AML
and
myeloma immunotherapy
.